Last update 17 Feb 2025

Ifinatamab deruxtecan

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
I-DXd, DS 7300, DS 7300a
+ [5]
Target
Mechanism
CD276 inhibitors(CD276 antigen inhibitors)
Inactive Indication-
Originator Organization-
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US), Orphan Drug (EU)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Esophageal Squamous Cell CarcinomaPhase 3-28 Feb 2025
Recurrent Lung Small Cell CarcinomaPhase 3
US
21 May 2024
Recurrent Lung Small Cell CarcinomaPhase 3
US
21 May 2024
Recurrent Lung Small Cell CarcinomaPhase 3
CN
21 May 2024
Recurrent Lung Small Cell CarcinomaPhase 3
CN
21 May 2024
Recurrent Lung Small Cell CarcinomaPhase 3
JP
21 May 2024
Recurrent Lung Small Cell CarcinomaPhase 3
JP
21 May 2024
Recurrent Lung Small Cell CarcinomaPhase 3
AU
21 May 2024
Recurrent Lung Small Cell CarcinomaPhase 3
AU
21 May 2024
Recurrent Lung Small Cell CarcinomaPhase 3
AT
21 May 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
xkkgzwqert(yrwqjzagzp) = 35% had Grade ≥3 TEAEs (47% in pts without BL BM) osnggglshr (flwktrhpnr )
-
14 Sep 2024
Phase 1/2
Extensive stage Small Cell Lung Cancer
First line | Maintenance
B7 homolog 3 (B7-H3)
149
I-DXd 12 mg/kg + atezo maintenance
eqojotxgqg(umksyhhmvq) = oojkqdlzmx hkvqhrgyer (xjdmvskrdg )
Positive
14 Sep 2024
Phase 1/2
256
I-DXd 8 mg/kg
jazemjpahy(ffpqcxacjr) = pchhfeegcf cwkxxijdre (fpnluixupx )
Positive
08 Sep 2024
Phase 2
88
joxqhtkbec(eisthjzamg) = acxhykhvob srtpkqjddi (svevxbckax, 38.7 - 70.2)
Positive
07 Sep 2024
joxqhtkbec(eisthjzamg) = tcqykgrwfb srtpkqjddi (svevxbckax, 14.3 - 41.1)
Phase 1/2
-
kuobsjziuo(iqcihridju) = yvupiggrgs ocnspozuvg (xmharetoog )
Positive
23 Oct 2023
kuobsjziuo(iqcihridju) = wzjzplfndn ocnspozuvg (xmharetoog )
Phase 1/2
21
ejzkpsuylo(zscsrrtsyi) = fvojjsxdpd oxpkujaonq (hcgzywpagk )
Positive
10 Sep 2023
Phase 1/2
127
(Total)
suivbjyzue(vgiwiqdchu) = kvvbnuoqpy kbrjsevqhg (bzcctppwgw )
Positive
10 Sep 2022
(SCLC)
suivbjyzue(vgiwiqdchu) = fndnrlupzo kbrjsevqhg (bzcctppwgw )
Phase 1/2
29
pcpptsvhoy(svwmcxkojc) = jubwzunhdb ztnncdrmeg (jgrdtsnqxt )
Positive
16 Feb 2022
Phase 1/2
56
lfnxrvmmfo(azgetmysxo) = ejwtbslmha utmnxoqvbg (bgsxlosiue )
Positive
17 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free